The effect of thymosin treatment of venous ulcers
Guarnera G, DeRosa A, Camerini R, et al. Annals of the New York Academy of Sciences 2010;1194:207-212.
What it found
Phase 2, double-blind, placebo-controlled, at eight European sites. All doses had a safety profile comparable to placebo. The authors suggest 0.03% may speed healing and report complete healing within 3 months in about 25% of patients, but the abstract gives no direct comparison with placebo.
Limitations
Full protein, not the fragment. Efficacy is described as suggestive rather than proven. Published in a conference volume.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.